Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc.
Your view on AUPH
Overview
What the company does, where it operates, and who runs it.
About Aurinia Pharmaceuticals Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Peter S. Greenleaf
- Headquarters
- 4464 Markham Street, Edmonton, BC, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Peter S. Greenleaf
- Headquarters
- 4464 Markham Street, Edmonton, BC, CA
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Aurinia Pharmaceuticals Inc., and the rating behind it. AUPH last traded at $16.10, 6.8× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Aurinia Pharmaceuticals Inc.. Starting points for Aurinia Pharmaceuticals Inc.: P/E 6.8, EPS $2.41, beta 1.41 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Aurinia Pharmaceuticals Inc.. Aurinia Pharmaceuticals Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Aurinia Pharmaceuticals Inc.. Trailing twelve-month EPS for Aurinia Pharmaceuticals Inc. stands at $2.41. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Aurinia Pharmaceuticals Inc.. Aurinia Pharmaceuticals Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Aurinia Pharmaceuticals Inc. valued side by side against its closest peers. Aurinia Pharmaceuticals Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Aurinia Pharmaceuticals Inc., and how their positions are changing. At a $2.07B market value, institutional positions materially move Aurinia Pharmaceuticals Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Aurinia Pharmaceuticals Inc. executives and directors. Shares of Aurinia Pharmaceuticals Inc. have traded between $6.55 and $16.20 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Aurinia Pharmaceuticals Inc.. Aurinia Pharmaceuticals Inc. is a $2.07B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Aurinia Pharmaceuticals Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Aurinia Pharmaceuticals Inc.. Coverage tracks Aurinia Pharmaceuticals Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.